| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.082 | 0.03 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.03 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.03 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.061 | 0.03 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.082 | 0.03 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.03 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |